Aegerion Pharmaceuticals


Aegerion: Deutsche Bank Questioned Management’s Ability To Execute

In a research report issued today, Deutsche Bank analyst Robyn Karnauskas downgraded shares of Aegerion Pharmaceuticals (NASDAQ:AEGR) to Hold from Buy and reduced her …

Aegerion Shares Remain Undervalued Given The Significant Market Opportunity, Says Janney Capital

In a research report released yesterday, Janney Capital analyst Kimberly Lee reiterated a Buy rating on Aegerion Pharmaceuticals (AEGR) on the heels of …

Janney Capital Maintains Buy On Aegerion Ahead Of 2Q14 Earnings Report

In a research report released today, Janney Capital analyst Kimberly Lee maintained a Buy rating on Aegerion Pharmaceuticals (AEGR) with a $90 price target, which …